WASHINGTON – An experimental blood pressure drug once heavily promoted by Bristol-Myers Squibb is too risky to be sold, government advisers said Friday. The recommendation is a serious blow to the drug, Vanlev. Bristol-Myers had stoked expectations that Vanlev would become one of its next… Read More
Comments for: Blood pressure drug too risky, panel says
Blood pressure drug too risky, panel says
You may also like
Blood pressure drug too risky, panel says